Pharmaceutical News

RSS

Methamphetamine users more likely to develop Parkinson's disease

People who abused methamphetamine or other amphetamine-like stimulants were more likely to develop Parkinson's disease than those who did not, in a new study from the Centre for Addiction and Mental Health.

27 Jul 2011

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis, the process whereby new heart muscle cells are formed.

27 Jul 2011

FDA grants Orphan Drug Designation for Diffusion's TSC to treat glioblastoma multiforme

Diffusion Pharmaceuticals LLC announced today that trans sodium crocetinate (TSC), the company's lead drug candidate, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary brain cancer, also known as glioblastoma multiforme or GBM.

27 Jul 2011

PACA study: Adrenaline can treat cardiac arrest

Adrenaline has kept its place in cardiac arrest guidelines despite limited evidence for or against its use. The PACA study by Jacobs and colleagues, soon to be published in Resuscitation, the official journal of the European Resuscitation Council, provides the best evidence to date supporting the use of adrenaline to treat cardiac arrest.

27 Jul 2011

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Otsuka Canada Pharmaceutical Inc. (OCPI) announced today that Health Canada has issued a notice of compliance for SAMSCA (tolvaptan), the first medicine approved in Canada for the treatment of hyponatremia.

27 Jul 2011

Anavex presents data on neuroprotective evidence for lead compound for Alzheimer’s

Anavex Life Sciences Corp. is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease.”

26 Jul 2011

Physician-targeted education campaign reduces outpatient antibiotic use in Quebec

Antibiotic overuse and resistance have emerged as major threats during the past two decades. Following an outbreak of Clostridium difficile infections, which often result from antibiotic use, health care professionals in Quebec, Canada targeted physicians and pharmacists with an education campaign that reduced outpatient antibiotic use, according to a study published in Clinical Infectious Diseases and now available online.

26 Jul 2011

TikoMed receives FDA Orphan Drug Designation for TM-400 to treat hematological cancers

TikoMed AB, a biotechnology company focused on the development and commercialization of innovative treatments of immune diseases and transplantation therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted TM-400 Orphan Drug Designation for the mobilization of stem cells prior to stem cell transplantation treatment.

26 Jul 2011

VeganZyme supplement may aid in reducing digestive discomfort and symptoms

Every year the American public spends billions of dollars on food and beverages that are toxic to the body and devoid of natural enzymes. These may include processed, microwaved or cooked food, meat, cereal grains, milk, gluten, soy, refined sugar, and more. But are they really getting their money's worth? Not without a little extra help, says Dr. Edward F. Group III, DC, ND, a world-renowned authority on natural medicine and digestive health.

26 Jul 2011

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of "core-shell" nanoparticles for systemic delivery of RNAi therapeutics.

26 Jul 2011

Anesthetic agent isoflurane may treat intracerebral hemorrhage

The anesthetic agent isoflurane may be a useful treatment for intracerebral hemorrhage (ICH)—a type of stroke caused by bleeding inside the brain, reports a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

26 Jul 2011

EMA recommends orphan drug designation for 4SC's resminostat to treat HCC

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

26 Jul 2011

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.

26 Jul 2011

Diabetes drug rosiglitazone can reduce development of neuropathic pain

The diabetes drug rosiglitazone (Avandia) can control inflammation leading to nerve damage and abnormal pain responses, suggests a paper in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

26 Jul 2011

Prasco to market and distribute authorized generic of Shionogi's PONSTEL

Prasco Laboratories, the Authorized Generics company, announced today it has signed a supply agreement with Shionogi Inc. Under the terms of the agreement, Prasco will market and distribute Mefenamic Acid Capsules, USP 250 mg, the Authorized Generic version of Ponstel®. Prasco intends to begin shipping product immediately in the U.S. under the Prasco label.

25 Jul 2011

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold Pharmaceuticals, Inc., today announced that the University of Texas at San Antonio initiated a clinical trial of TH-302 in combination with bevacizumab in patients with recurrent high grade astrocytoma including glioblastoma.

25 Jul 2011

Ranbaxy announces launch of Letrozole Tablets in UK, Romania and France

Ranbaxy Laboratories Limited today announced the launch of Letrozole Tablets 2.5 mg in UK, Romania and France, on Day-1. Letrozole is the bio equivalent of Femara, the innovator product of Novartis, that has a market size of USD 58 Mn in UK, USD 95 Mn in France and USD 5.5 Mn in Romania.

25 Jul 2011

Pharmaceutical News

Methamphetamine users more likely to develop Parkinson's disease

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

FDA grants Orphan Drug Designation for Diffusion's TSC to treat glioblastoma multiforme

PACA study: Adrenaline can treat cardiac arrest

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Anavex presents data on neuroprotective evidence for lead compound for Alzheimer’s

Physician-targeted education campaign reduces outpatient antibiotic use in Quebec

TikoMed receives FDA Orphan Drug Designation for TM-400 to treat hematological cancers

VeganZyme supplement may aid in reducing digestive discomfort and symptoms

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Anesthetic agent isoflurane may treat intracerebral hemorrhage

EMA recommends orphan drug designation for 4SC's resminostat to treat HCC

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Diabetes drug rosiglitazone can reduce development of neuropathic pain

Prasco to market and distribute authorized generic of Shionogi's PONSTEL

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Ranbaxy announces launch of Letrozole Tablets in UK, Romania and France

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Swaziland government, Vantage plan to construct pharmaceutical manufacturing facility

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News